Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05DCL
|
|||
| Former ID |
DIB006615
|
|||
| Drug Name |
ZYT-1
|
|||
| Synonyms |
Lipid lowering molecule (dyslipidemia), Zydus-Cadila
Click to Show/Hide
|
|||
| Indication | Lipid metabolism disorder [ICD-11: 5C52.Z] | Phase 1 | [1] | |
| Company |
Zydus-Cadila Group
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thyroid hormone receptor beta (THRB) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Thyroid hormone signaling pathway | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Hematopoietic Stem Cell Differentiation | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01543269) A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.